@article{96faddfbe6384e369f1456287d5bf544,
title = "Association of plasma and cortical amyloid beta is modulated by APOE ε4 status",
abstract = "Background: Apolipoprotein E (APOE) ε4 allele's role as a modulator of the relationship between soluble plasma amyloid beta (Aβ) and fibrillar brain Aβ measured by Pittsburgh compound B positron emission tomography ([11C]PiB PET) has not been assessed. Methods: Ninety-six Alzheimer's Disease Neuroimaging Initiative participants with [11C]PiB scans and plasma Aβ1-40 and Aβ1-42 measurements at the time of PET scanning were included. Regional and voxelwise analyses of [ 11C]PiB data were used to determine the influence of APOE ε4 allele on association of plasma Aβ1-40, Aβ1-42, and Aβ1-40/Aβ1-42 with [11C]PiB uptake. Results: In APOE ε4- but not ε4+ participants, positive relationships between plasma Aβ1-40/Aβ1-42 and [11C]PiB uptake were observed. Modeling the interaction of APOE and plasma Aβ1-40/Aβ1-42 improved the explained variance in [11C]PiB binding compared with using APOE and plasma Aβ1-40/Aβ1-42 as separate terms. Conclusions: The results suggest that plasma Aβ is a potential Alzheimer's disease biomarker and highlight the importance of genetic variation in interpretation of plasma Aβ levels.",
keywords = "Alzheimer's Disease Neuroimaging Initiative, Alzheimer's disease, Amyloid beta, Apolipoprotein E, Mild cognitive impairment, Pittsburgh compound B, Plasma amyloid beta, Positron emission tomography",
author = "Shanker Swaminathan and Risacher, {Shannon L.} and Yoder, {Karmen K.} and West, {John D.} and Li Shen and Sungeun Kim and Mark Inlow and Tatiana Foroud and Jagust, {William J.} and Koeppe, {Robert A.} and Mathis, {Chester A.} and Shaw, {Leslie M.} and Trojanowski, {John Q.} and Holly Soares and Aisen, {Paul S.} and Petersen, {Ronald C.} and Weiner, {Michael W.} and Saykin, {Andrew J.}",
note = "Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) National Institutes of Health (NIH) grant U01AG024904 ; RC2AG036535 . ADNI is funded by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec, Inc.; Bristol-Myers Squibb Company; Eisai, Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Servier; Synarc, Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California at San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California at Los Angeles. This research was also supported by NIH grants ( P30AG010129 , K01AG030514 ), the Dana Foundation , U01AG032984 Alzheimer's Disease Genetics Consortium grant, NIA R01AG19771 , P30AG010133 , the Indiana Economic Development Corporation (IEDC no. 87884 ), and the Foundation for the National Institutes of Health for data analysis. We also thank the following people: genotyping at TGen: Matthew Huentelman, PhD, and David Craig, PhD; sample processing, storage, and distribution at the National Cell Repository for Alzheimer's Disease (NCRAD): Kelley Faber and Colleen Mitchell. Samples from the NCRAD, which receives government support under a cooperative agreement ( U24AG021886 ) awarded by the NIA were used in this study. We thank contributors who collected samples as well as patients and their families, whose participation and help made this work possible.",
year = "2014",
month = jan,
doi = "10.1016/j.jalz.2013.01.007",
language = "English (US)",
volume = "10",
pages = "e9--e18",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",
}